Sensei Biotherapeutics (NASDAQ:FTH) Hits New 12-Month High - Time to Buy?

Key Points

• Sensei Biotherapeutics shares surged 13.8% to a new 52-week high, trading near $38.61 and giving the company a market capitalization of approximately $1.01 billion.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and a $55 price target, although ratings range from “Strong Buy” to “Sell.” The company also exceeded quarterly EPS expectations, reporting a loss of $2.84 versus the expected loss of $5.04.
• Insiders purchased nearly 49,500 shares worth $1.19 million over the past 90 days, while institutional investors have also increased or initiated positions. Sensei is developing cancer and autoimmune-disease immunotherapies, including lead programs SIS-100 and SIS-101.

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH - Get Free Report) reached a new 52-week high on Wednesday . The company traded as high as $37.97 and last traded at $38.61, with a volume of 124897 shares trading hands. The stock had previously closed at $34.51.

Analyst Ratings Changes

FTH has been the subject of a number of analyst reports. Oppenheimer started coverage on Sensei Biotherapeutics in a research note on Tuesday, July 28th. They set an "outperform" rating and a $60.00 price objective for the company. Weiss Ratings assumed coverage on Sensei Biotherapeutics in a research note on Wednesday, June 17th. They issued a "sell (d-)" rating on the stock. Raymond James Financial started coverage on Sensei Biotherapeutics in a report on Friday, July 31st. They set an "outperform" rating and a $56.00 target price on the stock. Citizens Jmp assumed coverage on Sensei Biotherapeutics in a research report on Monday, July 20th. They set an "outperform" rating and a $51.00 target price for the company. Finally, Robert W. Baird assumed coverage on Sensei Biotherapeutics in a research note on Friday, June 26th. They issued an "outperform" rating and a $57.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $55.00.

Sensei Biotherapeutics Stock Up 13.8%

The business's 50 day moving average price is $28.93. The firm has a market capitalization of $1.01 billion, a PE ratio of -0.28 and a beta of -0.28.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, topping analysts' consensus estimates of ($5.04) by $2.20. As a group, sell-side analysts expect that Sensei Biotherapeutics, Inc. will post -13.18 EPS for the current year.

Insider Activity at Sensei Biotherapeutics

In related news, CFO Brian C. Stephenson acquired 5,000 shares of the firm's stock in a transaction on Wednesday, July 1st. The shares were purchased at an average cost of $23.50 per share, for a total transaction of $117,500.00. Following the completion of the acquisition, the chief financial officer directly owned 46,688 shares in the company, valued at approximately $1,097,168. This trade represents a 11.99% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Anand Kiran Parikh acquired 2,806 shares of the company's stock in a transaction dated Monday, June 22nd. The stock was bought at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the completion of the transaction, the chief executive officer directly owned 764,234 shares of the company's stock, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 49,494 shares of company stock worth $1,188,822 over the last 90 days. Corporate insiders own 7.00% of the company's stock.

Institutional Trading of Sensei Biotherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of FTH. Renaissance Technologies LLC raised its holdings in Sensei Biotherapeutics by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company's stock valued at $123,000 after acquiring an additional 1,100 shares during the period. Citadel Advisors LLC acquired a new position in shares of Sensei Biotherapeutics in the second quarter valued at approximately $307,000. Bank of America Corp DE increased its stake in shares of Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock worth $1,041,000 after purchasing an additional 32,719 shares during the period. Alyeska Investment Group L.P. bought a new position in shares of Sensei Biotherapeutics during the second quarter worth approximately $3,610,000. Finally, Stempoint Capital LP acquired a new stake in Sensei Biotherapeutics during the 1st quarter worth approximately $4,188,000. Institutional investors own 10.50% of the company's stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source